Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Biomind Labs Inc ( (TSE:BMND) ) is now available.
Biomind Labs Inc., a clinical-stage biopharmaceutical company focused on CNS disorders, develops novel drugs and nanotechnology-based delivery systems targeting psychiatric and neurological conditions. It applies translational neuroscience and formulation science to improve the pharmacological profiles of key molecules for unmet therapeutic needs.
At its recent Annual General & Special Meeting, Biomind shareholders voted in favour of all resolutions, including reappointing Davidson & Company LLP as auditor and confirming a five-member board led by CEO Alejandro Antalich. The meeting also reapproved the company’s Rolling Stock Option Plan and reaffirmed Antalich as CEO and Oscar Leon as CFO and Corporate Secretary, signaling continuity in governance and strategic direction.
More about Biomind Labs Inc
Biomind Labs Inc. is a clinical-stage biopharmaceutical company developing novel pharmaceutical drugs and proprietary nanotechnology-based delivery systems for psychiatric and neurological conditions affecting the central nervous system. Leveraging translational neuroscience and formulation science, the company seeks to optimize endogenous and naturally derived molecules to address unmet needs in CNS therapeutics through rigorous clinical validation and patient-centric innovation.
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$1.15M
See more data about BMND stock on TipRanks’ Stock Analysis page.